Antibody Information
General Information of This Antibody
| Antibody ID | ANI0UHCNZ |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | Zanidatamab |
|||||
| Organization | Zymeworks BC, Inc.; BeiGene Ltd. |
|||||
| Indication | Ovarian cancer; Gastric cancer |
|||||
| Synonyms |
ZW-25; ZW25; ZW 25
Click to Show/Hide
|
|||||
| Antibody Type | Monoclonal antibody (mAb) |
|||||
| Antibody Subtype | Humanized half-IgG1-kappa/(scFv-kappa-heavy)-h-CH2-CH3 |
|||||
| Antigen Name | Receptor tyrosine-protein kinase erbB-2 (HER2 ECD2); Receptor tyrosine-protein kinase erbB-2 (HER2 ECD4) |
Antigen Info | ||||
| ChEMBI ID | ||||||
| DrugBank ID | ||||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
| Heavy Chain Sequence |
GEVQLVESGGGLVQPGGSLRLSCAASGFTFADYTMDWVRQAPGKGLEWVGDVNPNSGGSI
YNQRFKGRFTFSVDRSKNTLYLQMNSLRAEDTAVYYCARNLGPSFYFDYWGQGTLVTVSS ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGG PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYVYPPSRDE LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFALVSKLTVDKSRW QQGNVFSCSVMHEALHNHYTQKSLSLSPG; GDIQMTQSPSSLSASVGDRVTITCRASQD VNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYC QQHYTTPPTFGQGTKVEIKGGSGGGSGGGSGGGSGGGSGEVQLVESGGGLVQPGGSLRLS CAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYL QMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSSAAEPKSSDKTHTCPPCPAPEL LGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREE QYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYVLPPS RDELTKNQVSLLCLVKGFYPSDIAVEWESNGQPENNYLTWPPVLDSDGSFFLYSKLTVDK SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG Click to Show/Hide
|
|||||
| Heavy Chain Varible Domain |
GEVQLVESGGGLVQPGGSLRLSCAASGFTFADYTMDWVRQAPGKGLEWVGDVNPNSGGSI
YNQRFKGRFTFSVDRSKNTLYLQMNSLRAEDTAVYYCARNLGPSFYFDYWGQGTLVTVSS Click to Show/Hide
|
|||||
| Heavy Chain Constant Domain 1 |
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS
GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKV Click to Show/Hide
|
|||||
| Heavy Chain Constant Domain 2 |
APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK
PREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK Click to Show/Hide
|
|||||
| Heavy Chain Constant Domain 3 |
GQPREPQVYVYPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS
DGSFALVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG Click to Show/Hide
|
|||||
| Heavy Chain Hinge Region |
EPKSCDKTHTCPPCP
Click to Show/Hide
|
|||||
| Heavy Chain CDR 1 |
GFTFADYT
Click to Show/Hide
|
|||||
| Heavy Chain CDR 2 |
VNPNSGGS
Click to Show/Hide
|
|||||
| Heavy Chain CDR 3 |
ARNLGPSFYFDY
Click to Show/Hide
|
|||||
| Light Chain Sequence |
GDIQMTQSPSSLSASVGDRVTITCKASQDVSIGVAWYQQKPGKAPKLLIYSASYRYTGVP
SRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYIYPATFGQGTKVEIKRTVAAPSVFIFP PSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTL TLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Click to Show/Hide
|
|||||
| Light Chain Varible Domain |
GDIQMTQSPSSLSASVGDRVTITCKASQDVSIGVAWYQQKPGKAPKLLIYSASYRYTGVP
SRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYIYPATFGQGTKVEIK Click to Show/Hide
|
|||||
| Light Chain Constant Domain |
RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD
SKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Click to Show/Hide
|
|||||
| Light Chain CDR 1 |
QDVSIG
Click to Show/Hide
|
|||||
| Light Chain CDR 2 |
SAS
Click to Show/Hide
|
|||||
| Light Chain CDR 3 |
QQYYIYPAT
Click to Show/Hide
|
|||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
Zanidatamab zovodotin [Phase 1 (discontinued)]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Objective Response Rate (ORR) |
28%
|
|||
| Patients Enrolled |
Eligible patients must have HER2-high advanced cancers (breast/GEA/others) progressing after standard therapies (trastuzumab-based regimens), measurable disease (expansion cohort), ECOG 0-1, adequate organ/cardiac function (LVEF ≥institutional normal).
|
||||
| Administration Dosage |
Dose Escalation: ZW49 administered intravenously at dose levels determined by the SMC
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT03821233 | Clinical Status | PHASE1 | ||
| Clinical Description |
A Phase 1 Study of ZW49 in Patients With Locally Advanced (Unresectable) or Metastatic HER2-Expressing Cancers
|
||||
| Primary Endpoint |
Safety assessments include DLTs (4 weeks), AEs/lab abnormalities/ECG-LVEF changes/dose reductions (7 months) graded by CTCAE v5.0 for ZW49-treated patients.
|
||||
| Other Endpoint |
Pharmacokinetics (serum concentrations), immunogenicity (ADAs), and efficacy outcomes (ORR/DCR/DOR/PFS per RECIST 1.1) are evaluated for up to 2 years in ZW49-treated cohorts.
|
||||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Disease control rate (DCR) |
72%
|
|||
| Patients Enrolled |
Eligible patients must have HER2-high advanced cancers (breast/GEA/others) progressing after standard therapies (trastuzumab-based regimens), measurable disease (expansion cohort), ECOG 0-1, adequate organ/cardiac function (LVEF ≥institutional normal).
|
||||
| Administration Dosage |
Dose Escalation: ZW49 administered intravenously at dose levels determined by the SMC
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT03821233 | Clinical Status | PHASE1 | ||
| Clinical Description |
A Phase 1 Study of ZW49 in Patients With Locally Advanced (Unresectable) or Metastatic HER2-Expressing Cancers
|
||||
| Primary Endpoint |
Safety assessments include DLTs (4 weeks), AEs/lab abnormalities/ECG-LVEF changes/dose reductions (7 months) graded by CTCAE v5.0 for ZW49-treated patients.
|
||||
| Other Endpoint |
Pharmacokinetics (serum concentrations), immunogenicity (ADAs), and efficacy outcomes (ORR/DCR/DOR/PFS per RECIST 1.1) are evaluated for up to 2 years in ZW49-treated cohorts.
|
||||